Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s | Enterpreneurship

Want create site? Find Free WordPress Themes and plugins.

A Pharmaceutical migraine-prevention has won approval, the second therapy in this new class to receive the regulatory nod this year.

The Friday approval for the Teva (NYSE: TEVA) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part of class of drugs called calcitonin gene-related peptides (CGRP). These antibody drugs work by blocking the CGRP protein, which is associated with migraine pain. The Amgen (NASDAQ: AMGN) CGRP drug erenumab (Aimovig) was approved in May.

Amgen’s migraine drug is a once-monthly… Read more »

UNDERWRITERS AND PARTNERS

Did you find apk for android? You can find new Free Android Games and apps.

You might also like More from author

Leave A Reply

Your email address will not be published.